Clinical Trial Update: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients [Phase 2]

View source ↗

Summary

Ongoing phase 2 trial of savolitinib for gastric cancer and esophagogastric junction adenocarcinoma; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Savolitinib (savolitinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Gastric Cancer, Esophagogastric Junction Disorder | Phase 2 | Status: ACTIVE_NOT_RECRUITING